RADVAX: A Stratified Phase I/II Dose Escalation Trial of Hypofractionated Radiotherapy Followed by Ipilimumab in Metastatic Melanoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms RADVAX
- 22 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 30 Dec 2011 New trial record